Assembly Biosciences Stock News

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development. The company is conducting preclinical work, with the aim of completing regulatory filings and initiating clinical studies as soon as possible in 2022. Read more

E-Home Household Service Holdings Limited (NASDAQ:EJH) with the stream of 8.38% also noticed, India Assembly Biosciences, Inc. (NASDAQ:ASMB) encountered a rapid change of 0.43% in the last hour of Tuesdays The post Stock Trending Alert: E-Home Household Service Holdings Limited (NASDAQ:EJH), Assembly Biosciences, Inc. (NASDAQ:ASMB) appeared first on Stocks Equity . Read more

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? Read more

Read more

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021. Read more

Read more

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Mr. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategic collaborations and transactions. Since joining Assembly Bio in 2017, Mr. Samar has led the companys financial and business operations, serving most recently as senior vice president of finance and business operations. Read more

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

Alibaba Group Holding Limited (NYSE:BABA) with the stream of 0.43% also noticed, India Assembly Biosciences, Inc. (NASDAQ:ASMB) encountered a rapid change of 0.29% in the last hour of Tuesdays trading The post Technical Secrets: Alibaba Group Holding Limited (NYSE:BABA), Assembly Biosciences, Inc. (NASDAQ:ASMB) appeared first on Stocks Equity . Read more

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc. Read more

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK) (announced Read more

Based on the historical situation of the past five years (2016-2020),GLOBAL INFO RESEARCH analyzes the overall scale of global Microbiome Drugs in the past few years, the scale of major regions, the scale and share of major enterprises, the scale of major product classifications, and the scale of major downstream applications. Scale analysis includes sales volume, price, [] Read more

Assembly Biosciences Inc (ASMB) shares closed today at 1.8% above its 52 week low of $3.33, giving the company a market cap of $136M. The stock is currently down 44.0% year-to-date, down 86.2% over the past 12 months, and down 42.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 31.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1209.9% The company's stock price performance over the past 12 months lags the peer average by 1368.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more

Assembly Biosciences Inc (ASMB) shares closed today at 1.8% above its 52 week low of $3.33, giving the company a market cap of $136M. The stock is currently down 44.0% year-to-date, down 85.8% over the past 12 months, and down 42.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 30.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1209.9% The company's stock price performance over the past 12 months lags the peer average by 1360.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected] © 2020 Kwhen Inc. Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ: ISEE) Moderna, Inc. (NASDA Read more